Cardiff Oncology
CRDF
82 hedge funds and large institutions have $479M invested in Cardiff Oncology in 2020 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 18 increasing their positions, 20 reducing their positions, and 19 closing their positions.
84% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 19
81% more capital invested
Capital invested by funds: $264M → $479M (+$215M)
22% more funds holding
Funds holding: 67 → 82 (+15)
0.55% more ownership
Funds ownership: 74.84% → 75.39% (+0.55%)
10% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 20
28% less call options, than puts
Call options by funds: $14.1M | Put options by funds: $19.5M
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Top Buyers
| 1 |
State Street
Boston,
Massachusetts
|
+$44.8M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$28.2M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$19.8M |
| 4 |
CA
Corriente Advisors
Fort Worth,
Texas
|
+$19.2M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$12.5M |
Top Sellers
| 1 |
VA
VR Adviser
New York
|
-$18M |
| 2 |
EI
EAM Investors
Solana Beach,
California
|
-$5.05M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$4.71M |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$4.34M |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$3.95M |
CRDF Hedge Fund Activity: Q4 2020 in Review
82 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Cardiff Oncology (CRDF) for Q4 2020, worth a combined $479M — up 81% from $264M a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new CRDF positions and 19 closed out — a net gain of 16 holders — while 18 added to existing stakes and 20 trimmed.
The largest buyer was State Street, opening a new position worth an estimated $44.8M. The largest seller was VR Adviser, exiting entirely with an estimated $18M sold.
- 82 institutional investors held Cardiff Oncology (CRDF) as of Q4 2020, up from 67 in Q3 2020.
- Funds reported $479M of Cardiff Oncology stock for Q4 2020, up 81% quarter-over-quarter.
- 35 funds opened new Cardiff Oncology positions in Q4 2020 and 19 closed out, a net change of +16 holders.
- The largest Cardiff Oncology buyer in Q4 2020 was State Street, an estimated $44.8M added.
- The largest Cardiff Oncology seller in Q4 2020 was VR Adviser, an estimated $18M sold.
Based on aggregated 13F filings for Q4 2020.